Interim report 2024, January 1 – March 31
The first quarter saw a continued favourable revenue development. The Lab segment delivered strong organic growth whereas our pharmaceuticals business affected the Group negatively. The changing product mix resulted in lower margins. Work continued to optimise the capital structure and profit for the period improved.January – March 2024 Net revenue for the period was SEK 413.4 million (310.5), an increase of 33.1% On an organic basis, net revenue declined by 9.5%. Excluding pharmaceuticals, organic growth was 3.6%. EBITDA for the period was SEK 99.1 million (84.2) Profit/loss